Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
C4 Therapeutics, Inc. (CCCC) had Free Cash Flow per Share of $-0.24 for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$6.15M |
|
$-25.13M |
|
-- |
|
$6.15M |
|
$33.94M |
|
$-27.79M |
|
$2.66M |
|
$-25.13M |
|
$-25.13M |
|
$-25.13M |
|
$-25.13M |
|
$-25.13M |
|
$-25.13M |
|
$-27.79M |
|
$-28.47M |
|
126.07M |
|
126.07M |
|
$-0.20 |
|
$-0.20 |
|
| Balance Sheet Financials | |
$245.37M |
|
$4.49M |
|
$83.49M |
|
$328.86M |
|
$27.25M |
|
-- |
|
$67.36M |
|
$94.61M |
|
$234.25M |
|
$234.25M |
|
$234.25M |
|
104.04M |
|
| Cash Flow Statement Financials | |
$-29.94M |
|
$16.15M |
|
$0.46M |
|
$78.05M |
|
$64.72M |
|
$-13.33M |
|
$2.67M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-451.64% |
|
-451.64% |
|
-- |
|
-408.47% |
|
-408.47% |
|
$-30.01M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
2.13 |
|
42.18 |
|
-10.73% |
|
-10.73% |
|
-7.64% |
|
-10.73% |
|
$2.25 |
|
|
Free Cash Flow per Share |
$-0.24 |
$-0.24 |
|